NexImmune, Inc. (NEXI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.13 Million USD | 90.68% |
| 2022 | -33.61 Million USD | -10.85% |
| 2021 | -30.32 Million USD | -315.29% |
| 2020 | 14.08 Million USD | -68.35% |
| 2019 | 44.5 Million USD | 28.54% |
| 2018 | 34.62 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.42 Million USD | 45.8% |
| 2024 Q1 | -4.47 Million USD | -42.74% |
| 2023 Q4 | -3.13 Million USD | 62.68% |
| 2023 Q3 | -8.39 Million USD | 45.95% |
| 2023 FY | -3.13 Million USD | 90.68% |
| 2023 Q1 | -21.42 Million USD | 36.26% |
| 2023 Q2 | -15.53 Million USD | 27.51% |
| 2022 Q3 | -44.7 Million USD | -13.59% |
| 2022 Q2 | -39.35 Million USD | -70.45% |
| 2022 FY | -33.61 Million USD | -10.85% |
| 2022 Q1 | -23.08 Million USD | 23.87% |
| 2022 Q4 | -33.61 Million USD | 24.8% |
| 2021 Q1 | -117.25 Million USD | -932.42% |
| 2021 FY | -30.32 Million USD | -315.29% |
| 2021 Q4 | -30.32 Million USD | 18.6% |
| 2021 Q3 | -37.25 Million USD | 40.84% |
| 2021 Q2 | -62.97 Million USD | 46.3% |
| 2020 FY | 14.08 Million USD | -68.35% |
| 2020 Q3 | 8.6 Million USD | 0.0% |
| 2020 Q4 | 14.08 Million USD | 63.7% |
| 2019 Q4 | -9.12 Million USD | 0.0% |
| 2019 FY | 44.5 Million USD | 28.54% |
| 2018 FY | 34.62 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 272.546% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 17.86% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 349.892% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 109.727% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -233.721% |
| Better Therapeutics, Inc. | -860 Thousand USD | -264.377% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 86.825% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 1054.096% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 168.57% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 46.185% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 197.988% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 198.957% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 162.648% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 102.338% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | 1849.173% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 125.397% |
| Molecular Templates, Inc. | 707 Thousand USD | 543.231% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 814.719% |
| Orgenesis Inc. | 21.78 Million USD | 114.385% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 219.788% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | -629145.582% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 33.477% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -2415.467% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 102.826% |
| Statera Biopharma, Inc. | 14.41 Million USD | 121.737% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 58.746% |
| Trevena, Inc. | 2.25 Million USD | 238.78% |
| Vaxxinity, Inc. | 10.13 Million USD | 130.928% |
| Vaccinex, Inc. | -1.28 Million USD | -143.295% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | 1009.763% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 123.67% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 4454.58% |